Cargando…

Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study

While there is strong epidemiological evidence that circulating insulin-like growth factor-I (IGF-I) is associated with a higher risk of several cancers, little is known about its association with non-cancer outcomes. We investigated associations of circulating IGF-I with risk of 25 common condition...

Descripción completa

Detalles Bibliográficos
Autores principales: Papier, Keren, Knuppel, Anika, Perez-Cornago, Aurora, Watts, Eleanor L., Tong, Tammy Y. N., Schmidt, Julie A., Allen, Naomi, Key, Timothy J., Travis, Ruth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791904/
https://www.ncbi.nlm.nih.gov/pubmed/34746972
http://dx.doi.org/10.1007/s10654-021-00811-y
_version_ 1784640289016643584
author Papier, Keren
Knuppel, Anika
Perez-Cornago, Aurora
Watts, Eleanor L.
Tong, Tammy Y. N.
Schmidt, Julie A.
Allen, Naomi
Key, Timothy J.
Travis, Ruth C.
author_facet Papier, Keren
Knuppel, Anika
Perez-Cornago, Aurora
Watts, Eleanor L.
Tong, Tammy Y. N.
Schmidt, Julie A.
Allen, Naomi
Key, Timothy J.
Travis, Ruth C.
author_sort Papier, Keren
collection PubMed
description While there is strong epidemiological evidence that circulating insulin-like growth factor-I (IGF-I) is associated with a higher risk of several cancers, little is known about its association with non-cancer outcomes. We investigated associations of circulating IGF-I with risk of 25 common conditions, other than cancer, in a large British cohort. Study participants were 318,749 middle-aged adults enrolled in the UK Biobank Study. Serum IGF-I concentration was measured in samples collected at baseline (2006–2010), and re-measured in 12,334 participants after an average of 4.3 years. We followed-up participants over an average of 11.5 years by linking to hospital admissions and mortality registries. Multivariable-adjusted Cox regressions estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between circulating IGF-I and 25 common conditions, using the repeated IGF-I measurements to correct for regression dilution bias. After correction for multiple testing (P < 0.002), IGF-I was positively associated with carpal tunnel syndrome (HR per 5 nmol/l higher concentration = 1.12, 95% CI 1.08–1.16), and inversely associated with varicose veins (0.90, 0.85–0.95), cataracts (0.97, 0.95–0.99), diabetes (0.92, 0.90–0.95), and iron deficiency anaemia (0.90, 0.86–0.93). The associations for cataracts and diabetes attenuated when restricted to cases diagnosed after five or more years of follow-up, suggesting that these associations were likely affected by reverse causality. Higher IGF-I concentration might be associated with the risk for several conditions, but genetic studies are needed to clarify which associations may be causal. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10654-021-00811-y.
format Online
Article
Text
id pubmed-8791904
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-87919042022-02-02 Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study Papier, Keren Knuppel, Anika Perez-Cornago, Aurora Watts, Eleanor L. Tong, Tammy Y. N. Schmidt, Julie A. Allen, Naomi Key, Timothy J. Travis, Ruth C. Eur J Epidemiol Morbidity While there is strong epidemiological evidence that circulating insulin-like growth factor-I (IGF-I) is associated with a higher risk of several cancers, little is known about its association with non-cancer outcomes. We investigated associations of circulating IGF-I with risk of 25 common conditions, other than cancer, in a large British cohort. Study participants were 318,749 middle-aged adults enrolled in the UK Biobank Study. Serum IGF-I concentration was measured in samples collected at baseline (2006–2010), and re-measured in 12,334 participants after an average of 4.3 years. We followed-up participants over an average of 11.5 years by linking to hospital admissions and mortality registries. Multivariable-adjusted Cox regressions estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between circulating IGF-I and 25 common conditions, using the repeated IGF-I measurements to correct for regression dilution bias. After correction for multiple testing (P < 0.002), IGF-I was positively associated with carpal tunnel syndrome (HR per 5 nmol/l higher concentration = 1.12, 95% CI 1.08–1.16), and inversely associated with varicose veins (0.90, 0.85–0.95), cataracts (0.97, 0.95–0.99), diabetes (0.92, 0.90–0.95), and iron deficiency anaemia (0.90, 0.86–0.93). The associations for cataracts and diabetes attenuated when restricted to cases diagnosed after five or more years of follow-up, suggesting that these associations were likely affected by reverse causality. Higher IGF-I concentration might be associated with the risk for several conditions, but genetic studies are needed to clarify which associations may be causal. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10654-021-00811-y. Springer Netherlands 2021-11-08 2022 /pmc/articles/PMC8791904/ /pubmed/34746972 http://dx.doi.org/10.1007/s10654-021-00811-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Morbidity
Papier, Keren
Knuppel, Anika
Perez-Cornago, Aurora
Watts, Eleanor L.
Tong, Tammy Y. N.
Schmidt, Julie A.
Allen, Naomi
Key, Timothy J.
Travis, Ruth C.
Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study
title Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study
title_full Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study
title_fullStr Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study
title_full_unstemmed Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study
title_short Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank study
title_sort circulating insulin-like growth factor-i and risk of 25 common conditions: outcome-wide analyses in the uk biobank study
topic Morbidity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791904/
https://www.ncbi.nlm.nih.gov/pubmed/34746972
http://dx.doi.org/10.1007/s10654-021-00811-y
work_keys_str_mv AT papierkeren circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT knuppelanika circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT perezcornagoaurora circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT wattseleanorl circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT tongtammyyn circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT schmidtjuliea circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT allennaomi circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT keytimothyj circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy
AT travisruthc circulatinginsulinlikegrowthfactoriandriskof25commonconditionsoutcomewideanalysesintheukbiobankstudy